Can cerebrospinal fluid biomarkers tell us something about financial capacity in Alzheimer's disease patients? A preliminary study.

IF 1.1 Q4 PSYCHIATRY

NEUROPSYCHIATRIE Pub Date : 2024-09-11 DOI:10.1007/s40211-024-00509-z

Vaitsa Giannouli, Magda Tsolaki

{"title":"Can cerebrospinal fluid biomarkers tell us something about financial capacity in Alzheimer's disease patients? A preliminary study.","authors":"Vaitsa Giannouli, Magda Tsolaki","doi":"10.1007/s40211-024-00509-z","DOIUrl":null,"url":null,"abstract":"Background: Although diagnostic markers in cerebrospinal fluid (CSF) have become a rapidly growing research field, they have not as yet been investigated in relation to capacities that are of interest to geriatric psychiatry and neuropsychology, such as financial capacity. The aim of this study was to assess whether CSF biomarkers can predict financial capacity in patients with a diagnosis of major neurocognitive disorder due to Alzheimer's disease (AD).Methods: Participants were examined with a number of neuropsychological tests, with an emphasis on the Mini-Mental State Examination (MMSE), the Geriatric Depression Scale (GDS-15), and the Legal Capacity for Property Law Transactions Assessment Scale (LCPLTAS) and CSF tests.Results: Amyloid β peptide 1-42 (Aβ42), total tau, and phosphorylated tau were not found to predict financial capacity performance in AD, but MMSE shows a strong positive correlation with LCPLTAS.Conclusions: These preliminary findings indicate that complex cognitive functions, such as financial capacity, may not be directly linked to CSF concentrations of the abovementioned biomarkers. Further studies with larger numbers of patients will be required to assess the reproducibility of these findings and to determine whether this approach can assist not only in diagnosis but also in neuropsychological assessment.","PeriodicalId":44560,"journal":{"name":"NEUROPSYCHIATRIE","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEUROPSYCHIATRIE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40211-024-00509-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Although diagnostic markers in cerebrospinal fluid (CSF) have become a rapidly growing research field, they have not as yet been investigated in relation to capacities that are of interest to geriatric psychiatry and neuropsychology, such as financial capacity. The aim of this study was to assess whether CSF biomarkers can predict financial capacity in patients with a diagnosis of major neurocognitive disorder due to Alzheimer's disease (AD).

Methods: Participants were examined with a number of neuropsychological tests, with an emphasis on the Mini-Mental State Examination (MMSE), the Geriatric Depression Scale (GDS-15), and the Legal Capacity for Property Law Transactions Assessment Scale (LCPLTAS) and CSF tests.

Results: Amyloid β peptide 1-42 (Aβ42), total tau, and phosphorylated tau were not found to predict financial capacity performance in AD, but MMSE shows a strong positive correlation with LCPLTAS.

Conclusions: These preliminary findings indicate that complex cognitive functions, such as financial capacity, may not be directly linked to CSF concentrations of the abovementioned biomarkers. Further studies with larger numbers of patients will be required to assess the reproducibility of these findings and to determine whether this approach can assist not only in diagnosis but also in neuropsychological assessment.

查看原文本刊更多论文

脑脊液生物标志物能否说明阿尔茨海默病患者的经济能力？一项初步研究。

背景：尽管脑脊液（CSF）中的诊断标志物已成为一个快速发展的研究领域，但迄今为止尚未对老年精神病学和神经心理学感兴趣的能力（如经济能力）进行研究。本研究的目的是评估 CSF 生物标志物能否预测因阿尔茨海默病（AD）而被诊断出患有严重神经认知障碍的患者的经济能力：对参与者进行了多项神经心理测试，重点是小型精神状态检查（MMSE）、老年抑郁量表（GDS-15）、财产法交易法律能力评估量表（LCPLTAS）和脑脊液测试：结果：未发现淀粉样β肽1-42（Aβ42）、总tau和磷酸化tau可预测AD患者的财务能力表现，但MMSE与LCPLTAS呈强正相关：这些初步研究结果表明，复杂的认知功能（如财务能力）可能与上述生物标志物的脑脊液浓度没有直接联系。还需要对更多患者进行进一步研究，以评估这些发现的可重复性，并确定这种方法是否不仅有助于诊断，还有助于神经心理评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NEUROPSYCHIATRIE PSYCHIATRY-

CiteScore

3.80

自引率

20.00%

发文量

期刊介绍： Die Zeitschrift ist das offizielle Organ der „Österreichischen Gesellschaft für Psychiatrie, Psychotherapie und Psychosomatik (ÖGPP)'', und wissenschaftliches Organ der Österreichischen Alzheimer Gesellschaft, der Österreichischen Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, der Österreichischen Schizophreniegesellschaft, und der pro mente austria - Österreichischer Dachverband der Vereine und Gesellschaften für psychische und soziale Gesundheit.Sie veröffentlicht Übersichten zu relevanten Themen des Fachs, Originalarbeiten, Kasuistiken sowie Briefe an die Herausgeber. Zudem wird auch Buchbesprechungen sowie Neuigkeiten aus den Bereichen Personalia, Standes- und Berufspolitik sowie Kongressankündigungen Raum gewidmet.Thematisch ist das Fach Psychiatrie und die Methoden der Psychotherapie in allen ihren Facetten vertreten. Die Zeitschrift richtet sich somit an alle Berufsgruppen, die sich mit Ursachen, Erscheinungsformen und Behandlungsmöglichkeiten von psychischen Störungen beschäftigen. -----------------------------------------------------------------------------------------------------· The professional and educational journal of the Austrian Society of Psychiatry, Psychotherapy and Psychosomatics (Österreichische Gesellschaft für Psychiatrie, Psychotherapie und Psychosomatik; ÖGPP) and the Austrian Society of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (Österreichische Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie; ÖGKJP)· Overviews of all relevant topics pertaining to the discipline· Intended for all occupational groups committed to the causes and manifestations of, as well as therapy options for psychic disorders· All manuscripts principally pass through a double-blind peer review process involving at least two independent expertsThe official journal of the Austrian Societies of Psychiatry, Psychotherapy and Psychosomatics (ÖGPP) and Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (ÖGKJP)The journal publishes overviews of relevant issues in the field, original work, case reports and letters to the editors. In addition, space is devoted to book reviews, news from the areas of personnel matters and professional policies, and conference announcements.Thematically, the discipline of psychiatry and the methods of psychotherapy are represented in all their facets. The journal is thus aimed at all professional groups committed to the causes and manifestations of, as well as therapy options for psychic disorders